Recent changes
Methods for Constructing Conjugates Using Ortho-Phthalaldehyde
USPTO published Patent Application US20260098054A1 disclosing methods for constructing conjugates using ortho-phthalaldehyde. The method involves reacting an amine-containing component with a thiol-containing component in comparable mole ratios to generate a conjugate bearing a substituted or unsubstituted 1-thio-isoindole structure. Inventors are Xuechen LI and Hey Pui CHEUNG. The application was filed on August 22, 2023.
Macrocycle and Hydrophobic Particle Method for Removing Polymers from Protein Solutions
USPTO published patent application US20260098055A1 for a method of removing free polymers from solutions containing hydrophobic proteins using macrocycles and/or hydrophobic particles. The application (CPC C07K 1/145) was filed September 7, 2023, with inventors including Barbara Maertens and colleagues. This pre-grant publication does not confer any enforceable rights.
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
6-Aryl Isoindolin-1-ones mGlu2 Modulators, Apr 09
Shionogi Monocyclic GLP-1 Receptor Agonist Patent Application
Shionogi & Co., Ltd. filed USPTO Patent Application US20260098031A1 for a monocyclic compound demonstrating GLP-1 receptor agonist activity, along with pharmaceutically acceptable salts. The compound, classified under CPC codes C07D 405/14 and A61K 31/4439, is intended for pharmaceutical use. The application, published April 9, 2026, claims priority to the September 2023 filing date.
Methods and Compounds for Restoring Mutant p53 Function
USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.
Novel Crystalline Form of Enavogliflozin and Preparation Method
The USPTO published patent application US20260098033A1 for a novel crystalline form of enavogliflozin, an SGLT2 inhibitor for diabetes treatment. The new form exhibits improved thermodynamic stability, reduced hygroscopicity, enhanced long-term storage characteristics, and faster drug absorption compared to prior known forms. The application includes the preparation method and covers pharmaceutical compositions containing the crystalline form.
2H-Benzotriazole Derivative for Treating Premature Ejaculation
USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.
Salts and Solid Forms of Piperidine-2,6-Dione for Treating Disorders
USPTO published patent application US20260098035A1 on April 9, 2026, covering novel salts and solid forms of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. Inventors Lianfeng HUANG, Daozhong ZOU, and Tsz Chung LAI filed the application on September 19, 2023, claiming pharmaceutical compositions for treating, preventing, and managing various disorders.
Heteroaryl Pyridazine Carboxamides For Cancer Treatment
The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.
Multi-Fused Ring Compound for Diabetes, Obesity
USPTO published patent application US20260098037A1 for a multi-fused ring compound targeting diabetes and obesity. The application (filed September 22, 2025 by inventors Baomin Liu, Yan Zhu, Jinfa Hu, and Yu Huang) claims a compound of formula (I), its stereoisomers, and pharmaceutical compositions containing the compound for treating metabolic diseases. This is a routine patent publication providing public notice of the pending application and its claimed scope.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
692 changes in last 7 days
Latest high priority updates
140 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.